A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

Published:2016-08-01 Issue:2 Volume:31 Page:393-402
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Verstovsek S,Talpaz M,Ritchie E,Wadleigh M,Odenike O,Jamieson C,Stein B,Uno T,Mesa R A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016215.pdf

Reference54 articles.

1. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

2. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740.

3. Stein BL, Cervantes F, Giles F, Harrison CN, Verstovsek S . Novel therapies for myelofibrosis. Leuk Lymphoma 2015; 56: 2768–2778.

4. Cervantes F . How I treat myelofibrosis. Blood 2014; 124: 2635–2642.

5. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123: e123–e133.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions;Molecular Diversity;2023-11-25

2. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis;Expert Opinion on Investigational Drugs;2023-10-03

3. A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases;Current Hematologic Malignancy Reports;2023-07-03

4. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer;Signal Transduction and Targeted Therapy;2023-05-19

5. In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs;Pathogenesis and Treatment of Leukemia;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3